{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-034910","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.127404+00:00","generated_at":"2026-05-30T01:25:26.593597+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GeoVax Q3 net loss $5.8M ($0.91/share); BARDA NextGen trial on track; special meeting adjourned","bullets":["Net loss $5.8M for Q3 2024 ($0.91/share) vs $8.4M ($4.75/share) in Q3 2023; nine-month net loss $16.7M ($4.52/share).","Revenue of $2.8M from BARDA/RRPV Project NextGen award (no revenue in prior year period).","Cash $8.6M at Sep 30, 2024, vs $6.5M at Dec 31, 2023.","BARDA Phase 2b trial of GEO-CM04S1 (10,000 patients) preparing for activation; sites confirmed.","Special Meeting adjourned without business due to lack of quorum (30.4% proxy turnout); reconvened Dec 18, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-034910","json":"https://secwatch.observer/filing/0001437749-24-034910.json","markdown":"https://secwatch.observer/filing/0001437749-24-034910.md","text":"https://secwatch.observer/filing/0001437749-24-034910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774924034910/0001437749-24-034910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774924034910/govx20241113_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:25:26.593597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}